Abstract
Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 495-501 |
| Number of pages | 7 |
| Journal | Annals of Dermatology |
| Volume | 31 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Discontinuation
- Psoriasis
- Remission
- Tumor necrosis factor antagonist
- Withdrawal
ASJC Scopus subject areas
- Dermatology
Cite this
Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission? / Kim, Byungsoo; Maverakis, Emanual; Raychaudhuri, Siba P.
In: Annals of Dermatology, Vol. 31, No. 5, 01.01.2019, p. 495-501.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission?
AU - Kim, Byungsoo
AU - Maverakis, Emanual
AU - Raychaudhuri, Siba P.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.
AB - Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.
KW - Discontinuation
KW - Psoriasis
KW - Remission
KW - Tumor necrosis factor antagonist
KW - Withdrawal
UR - http://www.scopus.com/inward/record.url?scp=85072703591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072703591&partnerID=8YFLogxK
U2 - 10.5021/ad.2019.31.5.495
DO - 10.5021/ad.2019.31.5.495
M3 - Review article
AN - SCOPUS:85072703591
VL - 31
SP - 495
EP - 501
JO - Annals of Dermatology
JF - Annals of Dermatology
SN - 1013-9087
IS - 5
ER -